Innovations

Innovative features of PlasmaCap EBA

In addition to the ability to effectively capture plasma proteins at high yield and purity, PlasmaCap EBATM is an elegant technology that was designed with innovative features aimed at resolving practical issues with conventional chromatography.

plasma-cap
plasma-cap
plasma-cap
plasma-cap
plasma-cap
plasma-cap

plasma-cap

PlasmaCap EBA Features

plasma-cap
Flexible choice of starting material

plasma-cap

  • Handles common buffers and plasma or plasma-derived materials with high particulate and viscosity allowing for manufacturing flexibility
plasma-cap

PlasmaCap EBA Features

plasma-cap
Flexible choice of starting material

plasma-cap

  • Handles common buffers and plasma or plasma-derived materials with high particulate and viscosity allowing for manufacturing flexibility
plasma-cap

PlasmaCap EBA Features

plasma-cap
Even distribution of material flow

plasma-cap

  • Gentle rotation of fluidizer creates even distribution of material flow to increase ligand-protein interaction for optimal capture yields
plasma-cap

PlasmaCap EBA Features

plasma-cap
Even distribution of material flow

plasma-cap

  • Gentle rotation of fluidizer creates even distribution of material flow to increase ligand-protein interaction for optimal capture yields
plasma-cap

PlasmaCap EBA Features

plasma-cap
Proprietary adsorbents for optimal protein capture

plasma-cap

  • High density (3.0 – 3.5 g/mL) tungsten-carbide agarose beads minimize adsorbent bed expansion requirements, reducing buffer usage and column sizes
  • Adsorbents consist of varying size distribution of beads (40 – 350 μm) allowing for an expanded bed with optimized surface area for plasma protein capture
  • Beads can be cross-linked to conventional ligands including:
    • – Affinity ligands
    • – Ion exchange ligands
    • – Mixed mode ligands
    • – Metal chelate ligands
  • Adsorbent manufacture is ISO 9001 certified
  • Proprietary adsorbents designed to facilitate regulatory approval of drug products:
    • – Adsorbent materials are generally regarded as safe for biopharmaceutical manufacturing
    • – Adsorbents have been documented to have no leachables or extractables
plasma-cap

PlasmaCap EBA Features

plasma-cap
Proprietary adsorbents for optimal protein capture

plasma-cap

  • High density (3.0 – 3.5 g/mL) tungsten-carbide agarose beads minimize adsorbent bed expansion requirements, reducing buffer usage and column sizes
  • Adsorbents consist of varying size distribution of beads (40 – 350 μm) allowing for an expanded bed with optimized surface area for plasma protein capture
  • Beads can be cross-linked to conventional ligands including:
    • – Affinity ligands
    • – Ion exchange ligands
    • – Mixed mode ligands
    • – Metal chelate ligands
  • Adsorbent manufacture is ISO 9001 certified
  • Proprietary adsorbents designed to facilitate regulatory approval of drug products:
    • – Adsorbent materials are generally regarded as safe for biopharmaceutical manufacturing
    • – Adsorbents have been documented to have no leachables or extractables
plasma-cap

PlasmaCap EBA Features

plasma-cap
Optimal expanded bed adsorption for efficient protein capture

plasma-cap

  • Material flow generates stable expanded adsorbent bed based on bead size (largest at bottom, smallest at top) keeping operations simple
  • Near plug-flow material movement reduces back mixing and convection currents minimizing residence time, reducing cycle time and operating costs
  • Void space in expanded adsorbent bed allows particulates, precipitates, and air bubbles to pass through with minimal effect on chromatography operations
plasma-cap

PlasmaCap EBA Features

plasma-cap
Optimal expanded bed adsorption for efficient protein capture

plasma-cap

  • Material flow generates stable expanded adsorbent bed based on bead size (largest at bottom, smallest at top) keeping operations simple
  • Near plug-flow material movement reduces back mixing and convection currents minimizing residence time, reducing cycle time and operating costs
  • Void space in expanded adsorbent bed allows particulates, precipitates, and air bubbles to pass through with minimal effect on chromatography operations
plasma-cap

PlasmaCap EBA Features

plasma-cap
High throughput plasma protein capture and elute

plasma-cap

  • Minimal pressure drop along the column; material throughput is limited by rates of ligand-protein interaction which allows high material throughput, reducing cycle time and operating costs
plasma-cap

PlasmaCap EBA Features

plasma-cap
High throughput plasma protein capture and elute

plasma-cap

  • Minimal pressure drop along the column; material throughput is limited by rates of ligand-protein interaction which allows high material throughput, reducing cycle time and operating costs
plasma-cap

Download this information as a PDF document

To learn more about how plasma protein manufacturers and other biomanufacturing organizations can take advantage
of PlasmaCap EBA, please contact us.

plasma-cap therapurebio-plasmacap

Disclaimer | Privacy Policy | Accessibility | Sitemap

PlasmaCap EBA is a trademark of Therapure Biopharma Inc.

Copyright ©2013 Therapure Biopharma Inc.

plasma-cap